SRR934850
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 54.632063074901446
- age_years
- 38
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.391
- NOTCH_SIGNALING+0.377
- HEDGEHOG_SIGNALING+0.369
- MITOTIC_SPINDLE+0.354
- ANDROGEN_RESPONSE+0.316
- PROTEIN_SECRETION+0.307
- TGF_BETA_SIGNALING+0.290
- CHOLESTEROL_HOMEOSTASIS+0.258
- WNT_BETA_CATENIN_SIGNALING+0.231
- G2M_CHECKPOINT+0.224
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.269
- DNA_REPAIR-0.213
- SPERMATOGENESIS-0.197
- ALLOGRAFT_REJECTION-0.195
- MYOGENESIS-0.117
- INTERFERON_GAMMA_RESPONSE-0.091
- COAGULATION-0.060
- TNFA_SIGNALING_VIA_NFKB-0.057
- KRAS_SIGNALING_DN-0.048
- IL6_JAK_STAT3_SIGNALING-0.046
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C138638F-C6CB-439B-BFF0-CF097E0B421E | — | — | 0.844 |
| 2 | MNG1193 | — | — | 0.802 |
| 3 | 32CED7C6-C413-4B5C-8A49-8AA2C97E582D | — | — | 0.784 |
| 4 | 7EDF85E0-24E3-43B6-8C00-BBA39235266E | — | — | 0.782 |
| 5 | 37415C2E-3112-47E6-8757-4D128E3447AE | — | — | 0.772 |
| 6 | SRR934758 | — | — | 0.751 |
| 7 | MNG683 | — | — | 0.749 |
| 8 | 2B70C69F-DE54-4C78-B326-5CCEE15916FB | — | — | 0.733 |
| 9 | SRR934727 | — | — | 0.726 |
| 10 | DE716AF0-930E-4747-B7FE-4AFAA45212DC | — | — | 0.725 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.391 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.377 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.369 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.354 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.316 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.307 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.258 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.231 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.224 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.222 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.209 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.166 | Inavolisib | — uncovered |
| APOPTOSIS | 0.128 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.124 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.103 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |